**7. Emerging therapy**

For last many years treatment of Graves' Disease has not been substantially changed. In future we can see some great change in management of GD as many newer drugs are under trials. These newer therapies are mainly directed to TSHreceptor. A human anti-TSHR monoclonal antibody (K1–70) is in a phase I trial of development [65]. A novel highly selective inhibitor for the TSHR is has promising potential for further development for the treatment of GO [66].
